Roche EGRF Outlook: Iressa Review Gives “Encouragement” To Tarceva
Executive Summary
Roche's outlook for Tarceva in non-small cell lung cancer received a "margin of encouragement" from the Iressa FDA advisory committee review, Pharmaceuticals Head William Burns said on a conference call Oct. 10
You may also be interested in...
OSI Endorses Apoptosis; Cell Pathways Deal Brings Two Clinical Candidates
OSI Pharmaceuticals is investing in a second oncologic research pathway via the proposed acquisition of Cell Pathways for $32 mil
OSI Endorses Apoptosis; Cell Pathways Deal Brings Two Clinical Candidates
OSI Pharmaceuticals is investing in a second oncologic research pathway via the proposed acquisition of Cell Pathways for $32 mil
Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI
Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said